Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia
NCT ID: NCT03284294
Last Updated: 2020-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
40 participants
INTERVENTIONAL
2020-04-15
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D for Schizophrenia
NCT01759485
Role of Vitamin D Supplementation in Schizophrenia
NCT03101319
Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
NCT02197286
Study of Vitamin D in the Severely Mentally Ill
NCT01169142
Alpha-lipoic Acid Adjunctive Therapy in Schizophrenia
NCT03788759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Oral placebo daily for 8 weeks
Placebo
Oral placebo daily for 8 weeks
Vitamin D
Vitamin D Cholecalciferol 2000 IU oral daily for 8 weeks
Cholecalciferol
cholecalciferol 2000 IU oral daily for 8 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cholecalciferol
cholecalciferol 2000 IU oral daily for 8 weeks
Placebo
Oral placebo daily for 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Serum 25(OH)D level below 30 ng/ml
* Deficit in cognitive functions
Exclusion Criteria
* Hepatic or renal failure
* Obese
* Metabolic syndrome
18 Years
45 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universitas Padjadjaran
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tuti Kurnianingsih
Principal Investigator
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PS-201709.01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.